Preclinical models of antipsychotic drug action
José L. Moreno, Javier González‐maeso
The International Journal of Neuropsychopharmacology June 10, 2013 DOI: 10.1017/s1461145713000606 via OpenAlex
Summary
AI-generated from the abstractPsychedelic drugs like LSD and dissociative drugs like PCP produce psychotic and cognitive symptoms in healthy people that resemble aspects of schizophrenia. Serotonin 5-HT2A and metabotropic glutamate 2 receptors are involved in how these drugs work. This review examines recent studies using LSD-like and PCP-like drugs in rodents that link these receptors to the biology of schizophrenia and its treatment.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | LSD Psilocybin Serotonin |
| Keywords | Phencyclidine Dissociative Hallucinogen Schizophrenia object-oriented programming |
| Citations | 30 |
| Key finding | Serotonin 5-HT2A and metabotropic glutamate 2 receptors are implicated in the neurobiology of schizophrenia and its treatment, based on rodent models using LSD-like and PCP-like drugs. |
Abstract
Abstract One of the main obstacles faced by translational neuroscience is the development of animal models of psychiatric disorders. Behavioural pharmacology studies indicate that psychedelic drugs, such as lysergic acid diethylamide (LSD) and dissociative drugs, such as phencyclidine (PCP), induce in healthy human volunteers psychotic and cognitive symptoms that resemble some of those observed in schizophrenia patients. Serotonin 5-HT2A and metabotropic glutamate 2 receptors have been involved in the mechanism of action of psychedelic and dissociative drugs. Here we review recent advances using LSD-like and PCP-like drugs in rodent models that implicate these receptors in the neurobiology of schizophrenia and its treatment.